

## IN THE CLAIMS

This listing of claims provided below will replace all prior versions and listings of claims in the application.

Claims 1-24 (canceled)

25 ~~26~~. (currently amended) A composition comprising a first ester prodrug of florfenicol, a second ester prodrug of florfenicol, and a pharmaceutically acceptable carrier, wherein the composition is formulated as a composition for administration to a mammal by injection ~~an injectable composition~~.

26 ~~27~~. (currently amended) The composition of claim 25 ~~26~~, wherein the concentration of the prodrugs of florfenicol in the composition is at least about 200 mg/mL.

27 ~~28~~. (currently amended) The composition of claim 25 ~~26~~, wherein at least one of the ester prodrugs of florfenicol is an ester formed between florfenicol and a carboxylic acid.

28 ~~29~~. (currently amended) The composition of claim 25 ~~26~~, wherein both the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are an ester formed between florfenicol and a carboxylic acid.

29 ~~30~~. (currently amended) The composition of claim 25 ~~26~~, wherein the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are selected from the group consisting of florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol pentanoate, florfenicol hexanoate, florfenicol heptanoate, florfenicol octanoate, florfenicol nanoate, florfenicol decanoate, florfenicol undecanoate, florfenicol dodecanoate, and florfenicol phthalate.

30 ~~31~~. (currently amended) The composition of claim 29 ~~30~~, wherein the first ester prodrug of florfenicol and the second ester prodrug of florfenicol are selected from the group consisting of florfenicol acetate, florfenicol propionate, florfenicol butyrate, florfenicol hexanoate, florfenicol phthalate.

31 32. (currently amended) The composition of claim 25 26, wherein the composition forms a drug depot when injected into a mammal.

32 33. (currently amended) The composition of claim 25 26, wherein the pharmaceutically acceptable carrier is selected from the group consisting of N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof.

33 34. (currently amended) The composition of claim 32 33, wherein the pharmaceutically acceptable carrier is selected from the group consisting of propylene glycol, glycerol formal, and combinations thereof.

34 35. (currently amended) A composition comprising florfenicol butyrate and a pharmaceutically acceptable solvent selected from N-methyl pyrrolidone, pyrrolidone, polyethylene glycol, propylene glycol, glycerol formal, isosorbid dimethyl ether, ethanol, dimethyl sulfoxide, tetrahydrofurfuryl alcohol, triacetin, and combinations thereof, wherein the composition is formulated as a composition for administration to a mammal by injection injectable.

35 36. (currently amended) The composition of claim 34 35, wherein the solvent is selected from propylene glycol, glycerol formal, and combinations thereof.

36 37. (currently amended) The composition of claim 35 36, wherein the pharmaceutically acceptable carrier is a combination of propylene glycol and glycerol formal.

37 38. (currently amended) The composition of claim 34 35, wherein the concentration of florfenicol butyrate in the composition is at least about 200 mg/mL.

38 39. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 25 26.

39 40. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 26 27.

40 ~~41~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 27 ~~28~~.

41 ~~42~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 28 ~~29~~.

42 ~~43~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 29 ~~30~~.

43 ~~44~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 30 ~~31~~.

44 ~~45~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 32 ~~33~~.

45 ~~46~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 34 ~~35~~.

46 ~~47~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 35 ~~36~~.

47 ~~48~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 36 ~~37~~.

48 ~~49~~. (currently amended) A method of treating a bacterial infection in a feline comprising injecting the feline with the pharmaceutical composition of claim 37 ~~38~~.